Accuray Incorporated
ARAY
NASDAQ·Healthcare·Medical - Devices·Mkt cap $31.7M
$0.27
▲ +0.30%
P/E
—
Mkt Cap
$31.7M
52-Wk Range
$0.22–$2.10
52-Week Range
$0.22 - $2.10
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 82.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary robotic radiosurgery technology with established clinical track record and FDA clearances
- Integrated treatment planning and data management ecosystem creating switching costs and customer lock-in
- Global distribution network with direct sales presence in major markets and partnerships in emerging regions
- Recurring revenue streams from service contracts, training, and software licensing
- Strong intellectual property portfolio protecting core radiosurgery and radiation therapy innovations
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Rising global cancer incidence and demand for non-invasive precision treatment modalities
Value
Deep value opportunity - significant discount to Medical Devices peers
Momentum
Falling
-24.7% over 3m
Quality
Stable
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ARAY right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 19, 2026
Reported EPS of -$0.02 vs -$0.03 consensus (+33.3% surprise). Revenue of $100.9M vs $105.3M expected (-4.2%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+33.3%
Revenue trend · last 8Q
—
—
+8%
+12%
-5%
-7%
-12%
-21%
Q4 24
Q1 24
Q2 24
Q3 25
Q4 25
Q1 25
Q2 25
Q4 26
$134.3M
$101.5M
$116.2M
$113.2M
$127.5M
$93.9M
$102.2M
$100.9M
Margins · last 8Q
Gross
35.2%
Operating
-7.0%
Profit
-1.9%
Wall Street consensus
2 analysts · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
—
Latest: Jefferies · May 12, 2026
vs Industry
How ARAY stacks vs Medical - Devices
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related